Roche/Trimeris’ Fuzeon Cited By FDA For Promotions At Scientific Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA letter cites claims made by Roche sales rep at last fall’s ICAAC, including that the injectable HIV therapy is “better than oral HIV drugs.” Rep also claimed that the drugs “confers ‘100% antiviral activity,’” FDA says.